TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio, Inc.

The latest update is out from TELA Bio ( ($TELA) ). On March 17, 2026, TELA Bio, Inc. was notified by Nasdaq that its common stock no longer met the


TELA Bio Faces Nasdaq Delisting, Plans Reverse Split

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TELA Bio (TELA) and Jazz Pharmaceuticals (JAZZ) with...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TELA	$1.26	-0.79%	150.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TELA	$1.26	-0.8%	150.61K
3
4
5
6

TELA

Get TELA Bio, Inc. Data in Excel

Get TELA Bio, Inc. Data in Excel